| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptability of generic versus innovator oral medicines: not only a matter of taste
|
Tuleu, Catherine
|
|
|
26 |
2 |
p. 329-343
|
artikel
|
| 2 |
Advanced magnetic resonance imaging to support clinical drug development for malignant glioma
|
Kassubek, Rebecca
|
|
|
26 |
2 |
p. 429-441
|
artikel
|
| 3 |
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet
|
Bender, Andreas
|
|
|
26 |
2 |
p. 511-524
|
artikel
|
| 4 |
A therapeutic update on PARP inhibitors: implications in the treatment of glioma
|
Lal, Samridhi
|
|
|
26 |
2 |
p. 532-541
|
artikel
|
| 5 |
Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays
|
Seyfoori, Amir
|
|
|
26 |
2 |
p. 455-473
|
artikel
|
| 6 |
Contents page 1
|
|
|
|
26 |
2 |
p. i
|
artikel
|
| 7 |
Contents page 2
|
|
|
|
26 |
2 |
p. ii
|
artikel
|
| 8 |
Desirable drug–drug interactions or when a matter of concern becomes a renewed therapeutic strategy
|
Guieu, Benjamin
|
|
|
26 |
2 |
p. 315-328
|
artikel
|
| 9 |
Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019
|
Lythgoe, Mark P.
|
|
|
26 |
2 |
p. 301-307
|
artikel
|
| 10 |
3D printing technology as innovative solutions for biomedical applications
|
Al-Dulimi, Zaisam
|
|
|
26 |
2 |
p. 360-383
|
artikel
|
| 11 |
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
|
Rizk, John G.
|
|
|
26 |
2 |
p. 593-603
|
artikel
|
| 12 |
Gene therapy in solid tumors: trends in trials in China and beyond
|
Chen, Kun
|
|
|
26 |
2 |
p. 296-300
|
artikel
|
| 13 |
Horizon Scanning for pharmaceuticals and effective health care programming: 2 years’ experience at the Italian Medicines Agency
|
Ivanovic, Jelena
|
|
|
26 |
2 |
p. 569-576
|
artikel
|
| 14 |
How can the potential of the duocarmycins be unlocked for cancer therapy?
|
Jukes, Zoë
|
|
|
26 |
2 |
p. 577-584
|
artikel
|
| 15 |
Integrating molecular modelling methods to advance influenza A virus drug discovery
|
Patel, Hershna
|
|
|
26 |
2 |
p. 503-510
|
artikel
|
| 16 |
Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
|
van Overbeeke, Eline
|
|
|
26 |
2 |
p. 399-415
|
artikel
|
| 17 |
Microtubule-targeting agents and neurodegeneration
|
Boiarska, Zlata
|
|
|
26 |
2 |
p. 604-615
|
artikel
|
| 18 |
Nanotechnology in the diagnosis and treatment of stroke
|
Sarmah, Deepaneeta
|
|
|
26 |
2 |
p. 585-592
|
artikel
|
| 19 |
Nitric oxide-releasing compounds for the treatment of lung infections
|
Chiarelli, Laurent R.
|
|
|
26 |
2 |
p. 542-550
|
artikel
|
| 20 |
Oral meropenem for superbugs: challenges and opportunities
|
Raza, Aun
|
|
|
26 |
2 |
p. 551-560
|
artikel
|
| 21 |
Radiation proteome: a clue to protection, carcinogenesis, and drug development
|
Shukla, Sandeep Kumar
|
|
|
26 |
2 |
p. 525-531
|
artikel
|
| 22 |
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019
|
Bharate, Sonali S.
|
|
|
26 |
2 |
p. 384-398
|
artikel
|
| 23 |
Reviving an R&D pipeline: a step change in the Phase II success rate
|
Wu, Shuang S.
|
|
|
26 |
2 |
p. 308-314
|
artikel
|
| 24 |
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?
|
Findling, Oliver
|
|
|
26 |
2 |
p. 416-428
|
artikel
|
| 25 |
Small-molecule modulators of serine protease inhibitor proteins (serpins)
|
Kellici, Tahsin F.
|
|
|
26 |
2 |
p. 442-454
|
artikel
|
| 26 |
Smart nanotheranostic hydrogels for on-demand cancer management
|
Misra, Ranjita
|
|
|
26 |
2 |
p. 344-359
|
artikel
|
| 27 |
Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap
|
Starokozhko, Viktoriia
|
|
|
26 |
2 |
p. 283-288
|
artikel
|
| 28 |
The development of small-molecule inhibitors targeting CD47
|
Yu, Wei-Bang
|
|
|
26 |
2 |
p. 561-568
|
artikel
|
| 29 |
The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy
|
Nininahazwe, Lauraine
|
|
|
26 |
2 |
p. 490-502
|
artikel
|
| 30 |
Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
|
Haddad, Yazan
|
|
|
26 |
2 |
p. 289-295
|
artikel
|
| 31 |
Uncertainty quantification in drug design
|
Mervin, Lewis H.
|
|
|
26 |
2 |
p. 474-489
|
artikel
|
Tijdschrift beschrijving